Eli Lilly will deliver up to 600,000 doses of the investigational drug bebtelovimab, worth at least $720 million, to the US government. bebtelovimab is designed to treat mild to moderate COVID-19 in high-risk patients. The company will deliver only if the FDA approves the drug for emergency use.